A randomized, controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural ghanaian infants

Journal of Infectious Diseases

Volumn 213, Issue 11, 2016, Pages 1678-1685

  Armah, George ^a   Lewis, Kristen D C ^d,g   Cortese, Margaret M ^e   Parashar, Umesh D ^e   Ansah, Akosua ^b   Gazley, Lauren ^d,h,i   Victor, John C ^d   McNeal, Monica M ^f   Binka, Fred ^c   Steele, A Duncan ^d  

^a University of Ghana   (Ghana)

^b NAVRONGO HEALTH RESEARCH CENTRE   (Ghana)

^c UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Ghana)

^d PATH   (United States)

^e NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g Pneumonia Global Health Program   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

ⁱ Trillium Community Health Plan   (United States)

Author keywords

Developing countries; Immunization schedules; Immunogenicity; Infant; Randomized controlled trial; Rotavirus; Rotavirus vaccines; Vaccines

Indexed keywords

IMMUNOGLOBULIN A; ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; FEMALE; GHANAIAN; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; INFORMED CONSENT; MALE; MASS SCREENING; OPEN STUDY; PRIORITY JOURNAL; ROTAVIRUS INFECTION; RURAL AREA; SEROCONVERSION; BLOOD; CLINICAL TRIAL; GHANA; IMMUNIZATION; IMMUNOLOGY; PASSIVE IMMUNIZATION; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, VIRAL; FEMALE; GHANA; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; INFANT; MALE; ROTAVIRUS VACCINES;

EID: 84978768073     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw023     Document Type: Article

References (32)

1. World Health Organization. Rotavirus vaccines WHO position paper. Wkly Epidemiol Rec 2007; 82:285-96.
2. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-Associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-Analysis. Lancet Infect Dis 2012; 12:136-41.
3. Armah GE, Breiman RF, Tapia MD, et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine 2012; 30(suppl 1):A86-93.
4. Armah GE, Kapikian AZ, Vesikari T, et al. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J Infect Dis 2013; 208:423-31.
5. Binka FN, Anto FK, Oduro AR, et al. Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Trop Med Int Health 2003; 8:840-6.
6. Armah GE, Mingle JA, Dodoo AK, et al. Seasonality of rotavirus infection in Ghana. Ann Trop Paediatr 1994; 14:223-9.
7. Mwenda JM, Ntoto KM, Abebe A, et al. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis 2010; 202(suppl):S5-11.
8. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
9. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184-90.
10. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
11. Shin S, Anh DD, Zaman K, et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine 2012; 30(suppl 1):A106-13.
12. Ali SA, Kazi AM, Cortese MM, et al. Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trial. J Infect Dis 2014; 210:1772-9.
13. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
14. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14.
15. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
16. Tapia MD, Armah G, Breiman RF, et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 2012; 30(suppl 1):A79-85.
17. Zaman K, Sack DA, Yunus M, et al. Successful co-Administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009; 27:1333-9.
18. Wood D. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005. Vaccine 2005; 23:5478-87.
19. Steele AD, De VB, Tumbo J, et al. Co-Administration study in South African infants of a live-Attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010; 28:6542-8.
20. Parashar UD, Glass RI. Rotavirus vaccines-early success, remaining questions. N Engl J Med 2009; 360:1063-5.
21. Madhi SA, Kirsten M, Louw C, et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012; 30(suppl 1):A44-51.
22. Gentsch JR, Glass RI, Woods P, et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992; 30:1365-73.
23. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990; 28:276-82.
24. Ward RL, Bernstein DI, Shukla R, et al. Protection of adults rechallenged with a human rotavirus. J Infect Dis 1990; 161:440-5.
25. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381-7.
26. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22:2836-42.
27. Cunliffe NA,Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012; 30(suppl 1):A36-43.
28. Anh DD. National Development and Licensure of a Human Monovalent Rotavirus Vaccine (ROTAVIN-M1) in Vietnam. 2012.
29. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008; 8:642-9.
30. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol 2012; 2:419-25.
31. Cheuvart B, Neuzil KM, Steele AD, et al. Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother 2014; 10:505-11.
32. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-Conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220-36.